Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 12/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645464 | 0.82 | HSP90AA1 (0.58) | HSP90AA1NOTUM | |
| SCHEMBL4937213 | 0.80 | HSP90AA1 (0.41) | HSP90AA1SMN1; SMN2 | |
| SCHEMBL4941779 | 0.77 | HSP90AA1 (0.52) | HSP90AA1NOTUMHTTSMN1; SMN2 | |
| SCHEMBL646966 | 0.76 | HSP90AA1 (0.52) | HSP90AA1ACLY | |
| SCHEMBL4942328 | 0.76 | TSHR (0.41) | HSP90AA1HTTSMN1; SMN2CYP2C9 | |
| SCHEMBL4937144 | 0.75 | HSP90AA1 (0.53) | HSP90AA1NOTUMSMN1; SMN2 | |
| SCHEMBL4933407 | 0.75 | HSP90AA1 (0.55) | HSP90AA1NOTUMHTTSMN1; SMN2 | |
| SCHEMBL4938769 | 0.73 | HSP90AA1 (0.59) | HSP90AA1 | |
| SCHEMBL4939661 | 0.73 | HSP90AA1 (0.59) | HSP90AA1SMN1; SMN2 | |
| SCHEMBL4935357 | 0.72 | HSP90AA1 (0.72) | HSP90AA1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618285-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| EP-1853570-B1 | HSP90-INHIBITING TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| EP-2023922-B1 | TRIAZOLE DERIVATIVES II | MERCK PATENT GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-8119795-B2 | Triazole derivatives II | MERCK PATENT GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100022540-A1 | TRIAZOLE DERIVATIVES II | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20080182857-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022540-A1 | TRIAZOLE DERIVATIVES II | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885NOTUM 4516/4885PTGER1 2508/4885 |
| US-20080182857-A1 | Triazole Derivatives | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885NOTUM 4417/4885PTGER1 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.